Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R Itzykson
Long-Term Outcome of Anemic Lower-Risk Myelodysplastic Syndromes Without 5q Deletion Refractory to or Relapsing After Erythropoiesis-Stimulating Agents
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Is There a Role for All-Trans Retinoic Acid in Combination With Recombinant Erythropoetin in Myelodysplastic Syndromes? A Report on 59 Cases
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Long-Term Outcome of Immunosuppressive Therapy for Japanese Patients With Lower-Risk Myelodysplastic Syndromes
International Journal of Hematology
Hematology
Blood Consult: Treating Del(5q) Myelodysplastic Syndromes
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Cryptic 5q Deletion in a Patient With Myelodysplastic Syndrome
British Journal of Haematology
Hematology
Myelodysplastic Syndromes With a Deletion 5q Display a Characteristic Immunophenotypic Profile Suitable for Diagnostics and Response Monitoring
Haematologica
Hematology
Long-Term Outcome After Anterior Cervical Discectomy Without Fusion
European Spine Journal
Surgery
Orthopedics
Sports Medicine
Effect of Long-Acting Erythropoiesis-Stimulating Agents on Hemoglobin Levels at the Initiation of Dialysis
Renal Replacement Therapy
Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide
Haematologica
Hematology
Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
